PT - JOURNAL ARTICLE AU - Syed-Abdul, Shabbir AU - Babu, A. Shoban AU - Bellamkonda, Raja Shekhar AU - Itumalla, Ramaiah AU - Acharyulu, GVRK AU - Krishnamurthy, Surya AU - Santosh Ramana, Y. Venkat AU - Mogilicharla, Naresh AU - Malwade, Shwetambara AU - (Jack) Li, Yu-Chuan TI - Using Artificial Intelligence-based models to predict the risk of Mucormycosis among COVID-19 Survivors: An Experience from India AID - 10.1101/2021.09.13.21263511 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.13.21263511 4099 - http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263511.short 4100 - http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263511.full AB - Introduction India reported a severe public health challenge not only due to the COVID-19 outbreak but also the increasing number of associated mucormycosis cases since 2021. This study aimed at developing artificial intelligence-based models to predict the risk of mucormycosis among the patients at the time of discharge from the hospital.Methods The dataset included 1229 COVID-19 positive patients, and additional 214 inpatients, COVID-19 positive as well as infected with mucormycosis. We used logistic regression, decision tree, and random forest, and the extreme gradient boosting algorithm. All our models were evaluated with 5-fold validation to derive a reliable estimate of the model error.Results The logistic regression, XGBoost, and random forest performed equally well with AUROC 95.0, 94.0, and 94.0 respectively. This study also determined the top five variables namely obesity, anosmia, de novo diabetes, myalgia, and nasal discharge, which showed a positive impact on the risk of mucormycosis.Conclusion The developed model has the potential to predict the patients at high risk and thus, consequently initiating preventive care or aiding in early detection of mucormycosis infection. Thus, this study holds potential for early treatment and better management of patients suffering from COVID-19 associated mucormycosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported in part by Ministry of Science and Technology, Taiwan [grant numbers 108-2221-E-038-013, 110-2923-E-038 -001 -MY3]; Taipei Medical University, Taiwan [grant numbers 108-3805-009-110, 109-3800-020-400]; Ministry of Education, Taiwan [grant number 108-6604-002-400]; Wanfang hospital, Taiwan [grant number 106TMU-WFH-01-4].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Gandhi Medical College & Hospital Institutional Ethical Committee, Secunderabad, Telangana, India (Rc. No. IEC/GMC/2021, dated 21/June/2021 "Predicting the risk of Mucormycosis among COVID-19 Survivors using Artificial Intelligence based models"). This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.